From lung scans to heart risk signals: what McLaren Health Care’s AI rollout reveals about preventive care
Discover how McLaren Health Care is using AI on routine CT scans to detect heart disease earlier and what it means for preventive cardiology.
Medical Devices & Diagnostics
Pharma & Biotech
Nimbus Therapeutics tests a dual inflammation and repair thesis with SIK2 inhibitors
Nimbus Therapeutics unveils SIK2 inhibitor data at ECCO 2026. Explore what this means for oral IBD therapies and mucosal healing strategies.
Medical Devices & Diagnostics
Henry Schein One and Align Technology deepen digital dentistry integration as workflow platforms take center stage
Henry Schein One integrates Align Technology iTero scanners into Dentrix platforms. Discover what this shift means for digital dentistry workflows and adoption.
Pharma & Biotech
Why Pfizer’s BRAFTOVI results could reshape first-line treatment for BRAF-mutant mCRC
Pfizer reports positive BREAKWATER data for BRAFTOVI in BRAF-mutant mCRC. Find out what this could change for frontline colorectal cancer care.
Pharma & Biotech
Bristol Myers Squibb pushes CELMoD frontier as FDA accepts iberdomide NDA in relapsed multiple myeloma
FDA accepts Bristol Myers Squibb’s iberdomide NDA for relapsed multiple myeloma. Find out what this CELMoD filing could change next.
Pharma & Biotech
Why Deciphera Pharmaceuticals’ tirabrutinib NDA matters for the future of CNS lymphoma therapy
FDA accepts tirabrutinib NDA for relapsed or refractory PCNSL. Find out what this means for CNS lymphoma treatment and regulatory strategy.
Pharma & Biotech
What the Invenra B-Body licensing deal changes for Twist Bioscience and antibody discovery services
Twist Bioscience licenses Invenra’s bispecific antibody platform. Find out how this reshapes biologics discovery infrastructure and industry dynamics.
Pharma & Biotech
Why Janux Therapeutics’ JANX011 trial could redefine immune reset in autoimmune disease
Janux Therapeutics begins first human study of JANX011. Find out how CD19 immune reset could change autoimmune treatment strategies.
Pharma & Biotech
Moleculin Biotech, Inc. secures Japanese IP boost as Annamycin enters pivotal Phase 3
Moleculin secures Japanese patent for Annamycin reconstitution. Discover what this means for AML development and global market strategy.
Pharma & Biotech
FDA IND clearance propels ViroMissile’s IDOV-Immune into major U.S. cancer centers
ViroMissile expands its IDOV-Immune Phase I trial to U.S. sites after FDA IND clearance. Discover what this means for systemic oncolytic therapy.